Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Sangamo Therapeutics (SGMO) over the last 10 years, with Q3 2025 value amounting to $977000.0.

  • Sangamo Therapeutics' Other Non-Current Liabilities fell 2127.32% to $977000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $977000.0, marking a year-over-year decrease of 2127.32%. This contributed to the annual value of $933000.0 for FY2024, which is 2139.85% down from last year.
  • As of Q3 2025, Sangamo Therapeutics' Other Non-Current Liabilities stood at $977000.0, which was down 2127.32% from $962000.0 recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Other Non-Current Liabilities peaked at $7.6 million during Q3 2021, and registered a low of $933000.0 during Q4 2024.
  • Over the past 5 years, Sangamo Therapeutics' median Other Non-Current Liabilities value was $1.2 million (recorded in 2023), while the average stood at $2.2 million.
  • Per our database at Business Quant, Sangamo Therapeutics' Other Non-Current Liabilities surged by 2292.52% in 2021 and then tumbled by 8289.98% in 2022.
  • Over the past 5 years, Sangamo Therapeutics' Other Non-Current Liabilities (Quarter) stood at $1.2 million in 2021, then fell by 0.82% to $1.2 million in 2022, then fell by 1.66% to $1.2 million in 2023, then fell by 21.4% to $933000.0 in 2024, then rose by 4.72% to $977000.0 in 2025.
  • Its last three reported values are $977000.0 in Q3 2025, $962000.0 for Q2 2025, and $933000.0 during Q1 2025.